Dr Reddy s to manufacture baricitinib for Covid treatment
By IANS |
Published on
Wed, May 12 2021 11:03 IST |
3 Views
Mumbai Port Trust to sign MoUs of worth Rs 1,860 cr at Maritime Summit. Image Source: IANS News
Hyderabad, May 12 : Pharma major Dr. Reddy s Laboratories Ltd on Wednesday announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for the manufacture and commercialization of baricitinib in India.
The drug baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, for use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Dr Reddyâs Enters Into Voluntary Licensing Agreement To Manufacture Baricitinib Used For Covid-19 Treatment
Dr. Reddyâs Laboratories Ltd (IANS)
Dr. Reddyâs Laboratories Ltd on Tuesday (11 May) announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for the manufacture and commercialization of the drug, baricitinib, in India.
The drug baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, for use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Pharma major Dr. Reddy s Laboratories Ltd on Friday announced that it has initiated the process with the Drugs Controller General of India (DCGI) for Emergency Use Authorization (EUA) of the well-studied human adenoviral vector-based platform .
Dr.Reddy s gets authorisation to start rolling out Sputnik V COVID-19 vaccine in India
IANSFeb 19, 2021, 17:58 IST
TOI
Hyderabad, Feb Pharma major Dr. Reddy s Laboratories Ltd on Friday announced that it has initiated the process with the
Drugs Controller General of India (
DCGI) for Emergency Use Authorization (
EUA) of the well-studied human adenoviral vector-based platform vaccine candidate,
Sputnik V.
As part of the review process, Dr. Reddy s will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by February 21, the Hyderabad-based firm said. Dr. Reddy s partnered with the Russian Direct Investment Fund (